Lesen Sie hier weiter... |  Drucken |  PDF

Ähnliche Artikel

• Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients With Atrial Fibrillation
• New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial With Multaq(R) (dronedarone) in Atrial Fibrillation
• American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation
• Landmark ATHENA Study Findings With Multaq(R)(dronedarone) Show 24% Reduction in Cardiovascular Hospitalisation or Death in Patients With Atrial Fibrillation
• Atrial Fibrillation Found to be Common in Patients With Atherothrombosis, Increases Risk of Cardiovascular Death, Heart Attack and Stroke
• First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes
• Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
• Sanofi-aventis Launches Major New Registry Including Over 10,000 Patients Worldwide With Atrial Fibrillation
• ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
• RecordAF Registry Will Provide First Global Insight Into Real Life Management of Atrial Fibrillation - A Major Cause of Cardiovascular Death and Hospitalization

Current Management - Tag - PRESSEMITTEILUNGEN

Paris (ots/PRNewswire) – – Multaq(R) Approved to Reduce the Risk of Cardiovascular Hospitalization in Patients With Atrial Fibrillation or Atrial

Dronedaron – Wikipedia

Trial with Dronedarone in Atrial Fibrillation or Flutter Patients for Information Multaq [2] Touboul P et al.: Dronedarone for prevention of atrial fibrillation: a dose

Presseportal: sanofi-aventis Group - Lassen Sie am Weltherz ...

Darüber hinaus gab nur einer von drei Risikopatienten an, dass sein Arzt bzw. 02.07.09 10:11 FDA Approves Multaq(R) for Patients With Atrial Fibrillation or Atrial Flutter

Presseportal: sanofi-aventis Group - Meilensteinstudie ATHENA ...

SAN und NYSE: SNY) gab heute bekannt, dass die Ergebnisse der Meilensteinstudie ATHENA zeigen, dass Multaq(R) FDA Approves Multaq(R) for Patients With Atrial Fibrillation or

Euronext - Tag - PRESSEMITTEILUNGEN

FDA Approves Multaq(R) for Patients With Atrial Fibrillation or Multaq(R) Approved to Reduce the Risk of Cardiovascular Hospitalization in Patients With Atrial Fibrillation